THE LANCET Oncology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. *Lancet Oncol* 2013; published online October 14. http://dx.doi.org/10.1016/S1470-2045(13)70442-X

ONLINE APPENDIX

In this online appendix, we provide detailed methodology and data sources used for the estimation of the costs of cancer in the European Union.

Table of contents:

A. Methodology and data sources
Health care utilisation
Primary care
Outpatient care
Accident & Emergency care
Hospital inpatient care
Healthcare unit costs
Medication expenditure
Non-health care utilisation
Informal care7
Mortality losses
Morbidity losses
References
B. Results
Table B.1 Average unit costs (€), by country, 2009
Table B.2. Cancer-related resource units per 1,000 population in the EU, by country, 2009
Table B.3. Total healthcare costs of cancer (€) by category of resource use and per capita, 2009
Table B.4 Costs of lung cancer (€ million) in the EU, by country, 2009
Table B.5 Costs of colorectal cancer (€ million) in the EU, by country, 2009
Table B.6 Costs of breast cancer (€ million) in the EU, by country, 2009
Table B.7 Costs of prostate cancer (€ million) in the EU, by country, 2009
Table B.8 Countries ranked in terms of cancer-related healthcare expenditure per capita 28
Figure B.1 Tornado plot of the results of the sensitivity analysis on the total costs of cancer in the EU, € billions, 2009
Figure B.2 Total healthcare costs (€) per capita and by healthcare service category, 2009, adjusted for price differentials
Figure B.3 Correlation between cancer healthcare expenditure (€) and national income (€, as measured using Gross Domestic Product – GDP)
Figure B.4 Correlation between cancer healthcare expenditure (€) and cancer incidence (crude)

Figure B.5 Total costs by cancer type, € million, 2009	32
Figure B.6 Proportion of health care expenditure by category and cancer type, 2009	32
Figure B.7 Healthcare costs per capita (\in) by cancer type and healthcare service category, 2009, adjusted for	ſ
price differentials (PPP)	33

A. Methodology and data sources

Health care utilisation

Dependant on the availability of data, the methods used to estimate cancer-related healthcare resource use fell in one of the following categories, in order of priority:

A. National cancer-specific data: Cancer-specific healthcare data were available for the whole population;

B. Survey/sample cancer-specific data: Cancer-specific healthcare data were available for a representative sample of the population either as the proportion of overall healthcare utilisation that was due to cancer or as healthcare utilisation rates per patient with cancer, e.g. annual outpatient visits per cancer patient;

C. National data but not cancer-specific: All-cause healthcare resource use data were available but not due to cancer. We estimated cancer-specific resource use by multiplying all-cause national data by the proportion of ambulatory visits due to cancer out of all ambulatory visits, if available. If cancer-related ambulatory information was not available, we used the proportion of hospital discharges due to cancer out of all discharges to allocate national healthcare utilisation;

D. No national data: we derived national utilisation data for all diseases from similar countries and allocated it into cancer using the approach defined in (C).

The methods used and respective data sources are reported in **Table A.1** and are discussed in greater detail in the following sections.

Primary care

Country-specific overall visits to primary care due to all conditions were obtained for all countries.¹⁻²⁸ To the total number of primary care visits we applied the proportion of primary care that was attributable to cancer using the following:

- 1) In Finland, data were available on the number of consultations per cancer patient ²⁹ which was multiplied by the total number of prevalent cases in the country. ³⁰
- 2) In Austria,³¹ Cyprus, ⁴ Denmark,³² Slovenia,³³ Sweden,³⁴ and the UK³⁵ published data were available on the proportion of primary consultations due to cancer.
- 3) In France,³⁶ data on ambulatory care expenditure by disease group were used to derive the number of visits due to cancer by applying the respective proportion of expenditure, out of all ambulatory expenditure, to the total number of primary care visits.⁹
- total number of primary care visits.⁹
 4) In Germany³⁷ and the Netherlands,^{38,39} data on ambulatory healthcare expenditure was available by disease group and cancer-attributable healthcare usage was derived by dividing cancer expenditure by the respective unit costs.^{39,41}
- 5) In Spain, the proportion of cancer-related outpatient visits out of all outpatient visits was available⁴² and was applied to the total number of primary care visits.²⁵.
- 6) In the remaining 16 countries, the proportion of hospital discharges due to cancer⁴³ out of all discharges was applied to the total number of primary care visits.

The proportion of primary care cancer visits due to cancer type was available for Germany,³⁷ the Netherlands³⁸ and the UK.³⁵ For all other countries, we evaluated the proportion of total cancer visits due to breast, lung, prostate and colorectal cancer from the proportion of cancer-related hospital discharges due to each cancer out of all cancer hospital discharges⁴³ and applied these to the total number of cancer-related primary care visits.

Outpatient care

Country-specific overall visits to outpatient care due to all conditions were obtained for all countries.^{1,3-12,14-16,18,21-24,26,44-55} To the total number of outpatient care visits we applied the proportion of care that was attributable to cancer using the following:

1) In Cyprus,⁴ Denmark,⁵⁶ Finland,⁵⁶ France,³⁶ Slovenia,³³ Spain,⁴², Sweden,⁵⁶ and the UK⁵⁷ published data were available on the proportion of primary consultations due to cancer.

- 2) In Germany ³⁷and the Netherlands, ^{38,39} data on outpatient healthcare expenditure by disease group was used to derive the number of visits due to cancer and its four subtypes by dividing expenditure by the unit costs of an outpatient visit. ³⁹⁻⁴¹
- 3) In the remaining 17 countries, the proportion of overall hospital discharges due to cancer⁴³ was applied to the total number of outpatient visits.

The proportion of outpatient care cancer visits due to cancer type was available for Germany,³⁷ the Netherlands³⁸ and Spain.⁴² For all other countries, we evaluated the proportion of total cancer visits due to breast, lung, prostate and colorectal cancer from the proportion of cancer-related hospital discharges due to each cancer out of all cancer hospital discharges⁴³ and applied these to the total number of cancer-related outpatient care visits.

Accident & Emergency care

Country-specific overall visits to A&E due to all conditions were obtained for 20 countries.^{1,4,6-8,17,45,50,52,53,58-70} National all-cause attendance figures were not available in 7 countries (Czech Republic, Greece, Latvia, Lithuania, Luxembourg, Slovenia, and Sweden) and A&E rates were derived from similar countries and applied to them. Therefore, for: 1) Czech Republic we used estimates from Slovakia;⁶⁸ 2) Latvia and Lithuania we used estimates from Estonia;⁷ 3) Luxembourg we used estimates from Belgium;⁵⁸ 4) Sweden we used estimates from Denmark;⁷¹ and 5) Greece and Slovenia we used estimates from a previous multicountry regression.⁷² To the total number of emergency care visits we applied the proportion of care that was attributable to cancer using the following:

- 1) National data on A&E visits were available for Denmark^{73,74} and Germany.⁶¹
- 2) Data on the proportion of A&E visits due to cancer were available for the UK,⁵⁷ based on results from a Scottish report.
- 3) In France³⁶ and the Netherlands,³⁸ data on outpatient expenditure by disease group were used to derive the number of A&E visits due to cancer, by applying the respective proportions of expenditure to the overall number of A&E visits.^{60,64}
- 4) For the remaining 22 countries, all-cause A&E visits were obtained and allocated into cancer using the proportion of overall hospital discharges due to cancer.⁴³

The proportion of emergency care cancer due to cancer type was available for Denmark,^{73,74} Germany⁶¹ and the Netherlands.³⁸ For all other countries, we evaluated the proportion of total cancer A&E visits due to breast, lung, prostate and colorectal cancer from the proportion of cancer-related hospital discharges due to each cancer out of all cancer hospital discharges⁴³ and applied these to the total number of cancer-related emergency care visits.

Hospital inpatient care

National data were available on cancer (including cancer type)-related days in hospital and day-cases in all countries,^{75,76} except Estonia, where we obtained age and gender-specific rates of cancer-related inpatient days from Latvia^{75,76} and applied these to the Estonian population in 2009.⁷⁷

Country	Primary care	Outpatient care	A&E	Inpatient care
Austria	B ^{1,31,77}	C ^{1,31,77}	C ^{1,31,77}	A 75.76
Belgium	C ^{2,43,77}	C ^{43,44,77}	C 43,58,77	A ^{75,76}
Bulgaria	C ^{3,43,77}	C ^{3,43,77}	C 43,59,77	A ^{75,76}
Cyprus	B 4.78	B ^{4.78}	C 4.78	A ^{75,76}
Czech Rep.	C ^{5,43}	C ^{5,43}	D ^{43,68,77}	A ^{75,76}
Denmark	B 6,32,74	B ^{6,56,74}	A ^{6,73,74}	A ^{75,76}
Estonia	C ^{7,43}	C ^{7,43}	C ^{7,43}	D ^{75,76}
Finland	B ^{8,29,30}	B ^{8,56}	C ^{8,56}	A ^{75,76}
France	C ^{9,36}	B ⁹	C ^{36,60}	A ^{75,76}
Germany	A ^{10,37,77}	A ^{10,37,77}	A 61	A ^{75,76}
Greece	C 11,43,77,79	C ^{11,43,77,79}	D ^{43,72,77}	A ^{75,76}
Hungary	C ^{12,43}	C ^{12,43}	C 43.62	A 75,76
Ireland	C ^{13,43}	$C^{43,45}$	C ^{43,45}	A ^{75,76}
Italy	C ^{11,43,74,77}	C ^{11,43,74,77}	C ^{43,63,77}	A ^{75,76}
Latvia	$C^{14,43,46}$	C 14,43,46	D ^{7,14,43,46}	A ^{75,76}
Lithuania	C 43,80	$C^{43,81}$	D ^{7,43,82}	A ^{75,76}
Luxembourg	C ^{16,43,74}	C ^{16,43,74}	D 43.58.77	A ^{75,76}
Malta	C ^{17,43}	C 43,47,77	C 17,43	A 75,76
Netherlands	A ^{18,38}	A ^{18,38}	C ^{38,64,77}	A ^{75,76}
Poland	C ^{19,43}	C 43,48	C 43,65	A 75,76
Portugal	$C^{20,43}$	$C^{43,49}$	C 43,66,77	A 75,76
Romania	C ^{21,22,43,77}	C ^{21,22,43,77}	C 43,67,83	A 75,76
Slovakia	C ^{23,43,77,84}	C 5.23,43,77,84	C 43.68	A ^{75,76}
Slovenia	A 24,33	A 24,55	D 33,45,72,77	A 75,76
Spain	C ^{25,42}	B ^{42,50}	C ^{42,50}	A 75,76
Sweden	B ^{26,34}	B ^{26,56}	D 56.71.74.77	A 75.76
UK	B ^{27,28,35}	B 52-55,57	B 52,53,57,69,85	A 75,76

Table A.1. Sources used to obtain healthcare resource use, by category and country.

A. National cancer-specific data: Cancer-specific healthcare data were available for the whole population;

B. Survey/sample cancer-specific data: Cancer-specific healthcare data were available for a representative sample of the population either as the proportion of overall healthcare utilisation that was due to cancer or as healthcare utilisation rates per patient with cancer, e.g. annual outpatient visits per cancer patient;

C. National data but not cancer-specific: All-cause healthcare resource use data were available but not due to cancer. We estimated cancer-specific resource use by multiplying all-cause national data by the proportion of ambulatory visits due to cancer out of all ambulatory visits, if available. If cancer-related ambulatory information was not available, we used the proportion of hospital discharges due to cancer out of all discharges to allocate national healthcare utilisation;

D. No national data: we derived national utilisation data for all diseases from similar countries and allocated it into cancer using the approach defined in (C).

Healthcare unit costs

For all countries, health care resource use was valued using country-specific unit costs, which fell in one the following categories, in order of priority:

A. Directly obtained from sources such as national fee schedules, published studies, national reports, World Health Organisation, etc.;

B. Derived from national expenditure figures (e.g. primary care, outpatient care, inpatient care) using the respective total activity levels. For example, cost per inpatient day was estimated by dividing the total inpatient expenditure by the total number of inpatient days;

C. Derived from the predictions of linear regression analyses of the unit costs of countries with available data. For: 1) outpatient care unit costs, we used the coefficients from the regression of outpatient unit costs on healthcare expenditure per capita; 2) A&E unit costs, we used the coefficients from the regression of outpatient unit costs on the number of hospital beds per capita and healthcare expenditure per capita; and 3) Inpatient bed day unit cost, we used the coefficients from the regression of inpatient unit cost on curative beds per capita, and healthcare expenditure per capita.

Sources of unit costs per country and resource use category are reported in Table A.2.

Country	Primary care	Outpatient care	A&E	Inpatient care
Austria	A 86.87	A ^{86,87}	A 39,88	B ^{75,76,89}
Belgium	A 90	A ⁹⁰	A 90	A ⁹¹
Bulgaria	B ^{3,89}	B ^{3, 89}	С	B ^{75,76,89}
Cyprus	A 92	A ⁹²	С	С
Czech Rep.	A 93	A ⁹³	С	A ⁹³
Denmark	B 71	B ⁷¹	A 39,94	A ^{39, 95}
Estonia	B ⁷	A ⁷	\mathbf{B}^{7}	B ⁷
Finland	A ^{39,96}	A ⁵⁶	A ^{39,97}	A ⁵⁶
France	B ⁹	B ⁹	A ⁹⁸	B ^{75,89}
Germany	А	А	A ^{39,99}	В
Greece	A ^{39,100}	A ^{39,101}	A 39,100	A ^{39,102}
Hungary	A ^{39,103}	A ^{39,62}	A ^{39,103}	A ^{39,62}
Ireland	A 39,104	A ^{39,104}	A 39,104	B ^{39,105,106}
Italy	A 39,107	A 39,108	A 39,109	A 39,110
Latvia	B^{46}	B^{46}	С	B^{-14}
Lithuania	B ¹⁵	B ¹⁵	С	B ¹⁵
Luxembourg	A 111	A 111	A 111	B ^{75,89}
Malta	B ¹⁷	С	A 39,112	A ^{39,112}
Netherlands	A 39,41	A 39,113	A 39,41	A 39,113
Poland	A 39,107	A 39,114	С	A 39,114
Portugal	A 115	B 116	${\bf B}^{116}$	B 116
Romania	A 39,117	A 39,117	С	B ^{75,89}
Slovakia	A ^{39,117}	A 39,117	С	B ^{75,89}
Slovenia	A 39,117	A 39,117	A 39,112	B 75,89
Spain	A 39,118	A ^{39,118}	A 39,118	A ^{39,118}
Sweden	A 119	A 39,56	A 39,120	A 39,120
UK	A ¹²¹	A ¹²²	A ¹²²	A ¹²²

Table A.2. Sources used to obtain healthcare unit costs, by category and country.

Medication expenditure

Medication expenditure consisted of the sum of retail and hospital sales of antineoplastic agents and endocrine therapy (ATC codes L1 and L2), and by country which were obtained from the IMS Health database. For Estonia, Greece, Luxembourg and Portugal, only retail sales data were available. Hospital sales in these countries were derived by applying the ratio of hospital to retail sales from similar countries. Therefore, for: 1) Estonia we used estimates from Latvia; 2) Greece and Portugal we used estimates from Spain; and 3) Luxembourg we used the average ratio from Belgium and France. For Cyprus, total sales on antineoplastic and immunomodulating agents (ATC code L) were available but not broken down by the respective sub-codes.^{89,123} Hence, expenditure on L1 and L2 drugs in Cyprus was estimated by applying the proportion of L1 and L2 sales out of all L sales from Greece. As no pharmaceutical sales data were identified for Malta, we converted Italian sales on antineoplastic agents to a cost per prevalent cancer and multiplied the resulting value by the number of prevalent cancers in Malta.¹²⁴ Finally, only Germany and the Netherlands provided information on the proportion of cancer-related medicine expenditure on the different types of cancer. Hence, the proportion of

pharmaceutical expenditure on cancer due to the four types of cancer was averaged across the two countries (i.e. 4% for colorectal, 4% for lung, 21% for breast and 22% for prostate cancer) and applied to total L1 and L2 sales in the remaining countries.

Non-health care utilisation

Informal care

We estimated the hours of informal care provided due to cancer using Wave 2 and Wave 3 of the SHARE survey¹²⁵ which collected data on 32,000 individuals resident in 13 EU countries in 2006 (Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Spain and Sweden). For countries not in SHARE, we combined data from similar countries that were in SHARE to obtain estimates for the 14 remaining countries. Therefore, for: 1) Bulgaria, Estonia, Hungary, Latvia, Lithuania, Romania, Slovakia and Slovenia we used pooled data from the Czech Republic and Poland; 2) For Finland we used pooled data from Denmark and Sweden; 3) for Cyprus, Malta and Portugal we used pooled data from Greece, Italy and Spain; and 4) for Luxembourg and the UK we used pooled data from Austria, Belgium, France, Germany, Ireland, and the Netherlands.

Hours of informal care for severely limited cancer patients were estimated by adding the age and sex-specific products of:

1) Prevalence of cancer, and each cancer under study, in the population: obtained from wave 2 of SHARE by logistic regression analysis after adjusting for age, gender, and country of residence;

2) Probability of being severely limited in daily activities due to cancer: obtained from wave 2 of SHARE by logistic regression after adjusting for age, gender, presence of cancer, presence of other health conditions, and country of residence;

3) Probability of receiving informal care due to cancer: obtained from wave 2 of SHARE using two logistic regressions (one for care from inside household and another for care outside the household) and adjusting for age, gender, presence of cancer, presence of other health conditions, and country of residence; and the 4) Hours of informal care received: obtained from wave 2 of SHARE by ordered logistic regression (almost daily, almost weekly, almost every month or less often) after adjusting for age, gender, presence of cancer, limitations in daily living, presence of other health conditions, and country of residence. These were converted into hours using the information from SHARE on the number of unpaid care hours (either daily, weekly, monthly or annually) patients with cancer received.

While informal care for severely limited cancer patients was informed by cancer participants in SHARE, the informal care for terminally ill patients was informed by participants that provided care to these patients. Hence, hours of informal care for terminally ill cancer patients was estimated by adding the age and sex-specific products of:

1) Number of cancer deaths;¹²⁶ and the

2) Probability of receiving informal care in the year before dying from cancer: Participants in wave 3 of SHARE were asked to report whether they had provided unpaid care for anyone who had died in the last year, including the age of the person to whom care was provided and the health conditions from which that person was suffering. The probability of providing informal care for a cancer patient was estimated using a logistic regression analysis and adjusting for age, gender and country; and the

3) Hours of informal care received: obtained from wave 3 of SHARE using an ordered logistic regression (less than one month, between one and 3 months, between 3 and 6 months, between 6 and 11 months, or for the full year) after adjusting for age, gender, presence of cancer, and country of residence. These were converted into hours using the information from SHARE on the number the hours of unpaid care provided each day.

Participants in SHARE were asked about the relationship between carer and person being cared (e.g. spouse, sibling, offspring, parent friend etc...). We assumed that spouses, siblings and friends providing the care would be of similar age to the patient, therefore carers of patients aged 65 years or more were assumed to be retired, and those carers of patients aged less than 65 years were assumed to be of working-age. If care was being provided by either the patients' children or their children's spouses, then it was assumed that these informal carers would be under 65 years of age. Using gender-specific economic activity and unemployment rates for each country,¹²⁷ we then determined the proportion of these carers who were employed or unemployed/economically inactive.

The mean net hourly wage rate was applied to informal care provided by those carers in working age and who were economically active and in employment.¹²⁸⁻¹³³ Annual earnings were adjusted to hourly wage rates, assuming there were 230 working days each year, and each day consisted of 8 hours of work. For those carers in retirement, unemployed, or economically inactive, the national hourly minimum wage was applied.¹³⁴ For those countries with no official minimum wage rate (Cyprus,¹³¹ Denmark,¹³⁵ Finland,¹³⁶ Germany,¹³⁶ Italy¹³⁶ and Sweden¹³⁶), the worst paid sector in the economy was proxied as a minimum wage.

Mortality losses

For all countries we assumed an initial working age of 15. Age and gender specific deaths due to cancer, and due to each of the four cancer types, were obtained for all countries from EUROSTAT.¹²⁶ The number of potential working years lost was then estimated as the difference between the age at death and maximum age of retirement (which we set at 79 years of age). However, this estimate would overestimate the total working years lost as not everyone will be economically active (i.e. either working or actively searching for work) or employed. Therefore, age- and gender-specific unemployment and activity rates for each of the 27 countries were applied to the potential foregone earnings due to premature mortality.¹²⁷ The total number of working years lost was then multiplied by gender-specific average annual earnings.

Morbidity losses

The costs associated with lost productivity due to morbidity were the costs associated with absence of work due to cancer. Morbidity losses could occur due to: individuals taking absence from leave for a defined period of time; or due to individuals being declared incapacitated or disabled due to their condition, and therefore leaving the labour market.

Temporary absence from work due to sickness

Country-specific overall annual days of sickness leave due to all conditions was obtained for all countries.^{7,24,26,74,133,137-155} To this we applied the proportion of sickness leave that was attributable to cancer, which was available in Austria,¹³⁷ Belgium,¹³⁸ Czech Republic,¹⁴⁰ Estonia,¹⁵⁶ France,¹⁵⁷ Germany,¹⁵⁸ Italy,¹⁵⁹ Luxembourg,¹⁴⁹ Netherlands,¹⁶⁰ Poland,¹⁵² Slovenia,¹⁶¹ Spain,¹⁶² and Sweden.¹⁶³ For Finland¹⁶⁴ and the UK,¹⁶⁵ we used the proportion of overall permanent absence from work due to cancer.

For countries where we could not establish the proportion of sickness leave attributable to cancer, we used proportions from other countries. Therefore, for: 1) Bulgaria, Hungary and Romania we used estimates from Poland;¹⁵² 2) Cyprus, Greece and Portugal we used estimates from Spain;¹⁶² 3) Denmark we used estimates from Sweden;¹⁶³ 4) Ireland we used estimates from the UK;¹⁶⁵ 5) Latvia and Lithuania we used estimates from Estonia;¹⁵⁶ 6) Malta we used estimates from Italy;¹⁵⁹ and 7) Slovakia we used estimates from the Czech Republic.¹⁴⁰

Except for Austria,¹³⁷ the Czech Republic,¹⁴⁰ France,¹⁶⁶ Germany,¹⁵⁸ and the UK¹⁶⁵ where the proportion of sickness leave/incapacity attributable to colorectal, lung, breast and prostate cancer was available, for all other countries the proportion of cancer-specific absent days from work due to colorectal, lung, breast and prostate cancer was obtained by assuming that this would be the same as the proportion of overall days in hospital due to each of these four cancers in the working age population.⁷⁵ We hypothesised that the higher the number of days spent in hospital, the higher the number of working days lost due to illness.

Permanent absence from work due to incapacity or disability

Country-specific information on the numbers of working-age individuals receiving incapacity or disability benefits and not being able to work due to all conditions was obtained for all countries.^{16,17,24,26,137,138,143,151,153, 164,166-180} To this we applied the proportion that was attributable to cancer, which was available in Finland;¹⁶⁴ France;¹⁶⁶ Slovenia;¹⁶¹ and the UK.¹⁶⁵ For Austria,¹³⁷ Belgium,¹³⁸ Czech Republic,¹⁴⁰ Estonia,¹⁵⁶ Germany,¹⁵⁸ Italy,¹⁵⁹ Luxembourg,¹⁴⁹ the Netherlands,¹⁶⁰ Poland,¹⁵² Spain¹⁶² and Sweden¹⁶³ we applied the proportion of sickness leave that was attributable to cancer. For countries where we could not establish the proportion of sickness leave attributable to cancer, we used proportions from other countries using the methodology to estimate temporary absence from work due to sickness.

For those countries where the proportion of sickness leave/incapacity attributable to colorectal, lung, breast and prostate cancer was unavailable, the proportion of cancer-specific incapacity cases due to colorectal, lung, breast

and prostate cancer was obtained by assuming that this would be the same as the proportion of overall days in hospital due to each of these four cancers in the working age population.⁷⁵

Valuing absence from work

The mean annual earnings identified when estimating informal care and mortality costs were converted to mean daily earnings. The product of working days lost and mean daily earnings provided the productivity losses associated with cancer, after adjusting for the 'friction period'.

Country	Temporary absence from work	Permanent absence from work
Austria	137	137
Belgium	75,138	75,138
Bulgaria	75,127,139,152	75,77,152,167
Cyprus	75,127,133,162	75,77,162,171
Czech Rep.	140	140,168
Denmark	75,141,163	75,127,163,169
Estonia	7,75,156	75,156,170
Finland	75,142,164	75,164
France	74,127,157,166	166
Germany	127,143,158	143,158
Greece	75,133,162	75,162,171
Hungary	75,144,152	75,152,172
Ireland	75,127,145,165	75,165,173
Italy	75,127,146,159	75,159,174
Latvia	75,147,156	75,156,175
Lithuania	75,148,156	75,156,176
Luxembourg	75,127,149	16,75,149
Malta	75,127,150,159	17,75,159
Netherlands	75,127,151,160	75,151,160
Poland	75,152	75,152,177
Portugal	75,127,153,162	75,153,162
Romania	75,127,152,154	75,152,167
Slovakia	127,140	140,178
Slovenia	24,75,161	24,75,161
Spain	74,75,127,162	75,162,179
Sweden	26,75,163	26,75,163
UK	127,155,165	165,180

Table A.3. Sources used to obtain morbidity losses, by country

References

- Statistics Austria. Ambulante Versorgung. http://www.statistik.at/web_de/statistiken/gesundheit/gesundheitsversorgung/ambulante_versorgung/ index.html. (accessed July 19, 2011).
 van der Heyden J. Contacts avec le médecin généraliste. https://www.wiv-
- *isp.be/epidemio/EPIFR/crospfr/hisfr/his08fr/r3/3_contactsmedecingeneraliste_gp_report3_fr.pdf.* (accessed November 9, 2011).
- 3 Georgieva L, Salchev P, Dimitrova R, Dimova A, Avdeeva O. Bulgaria: Health System Review. *Health Systems in Transition* 2007;**9**:1-156.
- 4 Republic of Cyprus. Health and hospital statistics 2008. Health Statistics. Series I. Report no. 29. http://www.mof.gov.cy/mof/cystat/statistics.nsf/All/22C9AA38A0E94851C2257726003DDA90/\$file/ HEALTH_HOSPITAL_STATS_2008-170510.pdf?OpenElement. (accessed March 10, 2011).
- 5 Institute of Health Information and Statistics of the Czech Republic. Activity of health establishments in selected branches of curative and preventive care 2009. http://www.uzis.cz/en/system/files/cinzdrz2009.pdf. (accessed November 14, 2011).
- 6 Statistics Denmark. Contacts covered by the public health insurance by region, type of benefits, age, sex and socioeconomic status. *http://www.statbank.dk/statbank5a/default.asp?w=1280* (accessed November 10, 2011).
- 7 Eesti Haigekassa. Estonian Health Insurance Fund Annual Report 2009. http://www.haigekassa.ee/uploads/userfiles/file/ENG/Eesti_Haigekassa_majandusaasta_aruanne_20 09_eng.pdf. (accessed November 11, 2011).
- 8 National Institute of Health and Welfare. Outpatient Health Care. http://uusi.sotkanet.fi/portal/page/portal/etusivu/hakusivu?group=357. (accessed November 11, 2011).
- 9 IRDES. Consommation en sante et activite medicale. *http://www.ecosante.org/*. (accessed August 3, 2011).
- 10 OECD. Doctors' consultations. OECD Health Data; 2009.
- 11 EUROSTAT. Healthcare resources. *http://www.europa.eu.int/*. (accessed August 3, 2011).
- 12 GYEMSZI National Institute for Quality- and Organizational Development in Healthcare and Medicines. Activity of the health care delivery system 1994-2009: Physician contacts: Family doctor's services total. *http://www.eski.hu/new3/adatok_en/adatok_tablazatok_en.php*. (accessed January 12, 2012).
- 13 Layte R, Barry M, bennett K, Brick A, Morgenroth E, Normand C, O'Reilly J, Thomas S, Tilson L, Wiley M, Wren M-A. Projecting the impact of demographic change on the demand for and delivery of health care in Ireland. *http://www.hrb.ie/uploads/tx_hrbpublications/Final_Report.ESRI.pdf*. (accessed December 15, 2011).
- 14 Nacionalais Veselibas Dienests. Yearbook of Health Statistics in Latvia, 2009. http://vec.gov.lv/uploads/files/4d00e9bb15825.pdf. (accessed January 10, 2012).
- 15 Health Information Centre of Institute of Hygiene. Health Statistics of Lithuania 2009. *http://sic.hi.lt/data/la2009.pdf.* (accessed January 18, 2012).

- 16 Ministere de la Securite Sociale. Rapport General sur la Securite Sociale au Grand-Duche de Luxembourg. *http://www.mss.public.lu/publications/rapport_general/rg2009/rg_2009.pdf*. (accessed January 5, 2012).
- 17 National Statistics Office Malta. Social Protection: Malta and the EU 2010. http://www.nso.gov.mt/statdoc/document_file.aspx?id=2953. (accessed January 5, 2012).
- 18 Statistics Netherlands. Use of medical facilities: Since 1981. *http://www.cbs.nl/en-GB/menu/themas/gezondheid-welzijn/nieuws/default.htm.* (accessed July 29, 2011).
- 19 Central Statistical Office of Poland. Local Data Bank. Outpatient Health Care Facilities: Primary health care (NTS-5, 2003-2011). *http://www.stat.gov.pl/bdlen/app/strona.html?p_name=indeks.* (accessed August 5, 2011).
- 20 Instituto Nacional de Estatistica. Consultas médicas (N.º) nos centros de saúde por Localização geográfica e Especialidade da consulta. *www.ine.pt.* (accessed February 29, 2012).
- 21 Vladescu C, Radulescu S, Olsavsky V. Health Care Systems in Transition: Romania. http://www.euro.who.int/__data/assets/pdf_file/0011/95924/E71423.pdf. (accessed July 1, 2011).
- 22 Vladescu C, Scintee G, Olsavsky V. Romania: Health System Review. *Health Systems in Transition* 2008; 10:1-172.
- 23 Szalay T, Pazitny P, Szalayova A, Frisova S, Morvay K, Petrovic M, van Ginneken E. Slovakia: Health System Review. *Health Systems in Transition* 2011;**13**:1-200.
- 24 Statistical Office of the Republic of Slovenia. Statistical Yearbook 2010. http://www.stat.si/letopis/letopisprvastran.aspx?lang=en. (accessed July 19, 2011).
- 25 Ministerio de Sanidad y Consumo. Sistema de Informacion de Atencion Primaria. http://pestadistico.msc.es/PEMSC25/ArbolNodos.aspx. (accessed July 27, 2011).
- Statistics Sweden. Statistical Yearbook of Sweden 2011.
 http://www.scb.se/Pages/PublishingCalendarViewInfo____259924.aspx?PublObjId=15284.
 (accessed November 3, 2011).
- 27 The Information Centre for Health and Social Care. Trends in consultation rates in General Practice 1995-2009. *http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/general-practice/trends-in-consultation-rates-in-general-practice--1995-2009*. (accessed May 10, 2011).
- 28 ISD Scotland. General Practice Total contacts by staff discipline. http://www.isdscotland.org/isd/1044.html#Summary. (accessed May 10, 2011).
- 29 Ovaskainen PT, Rautava PT, Ojanlatva A, Pakkila JK, Paivarinta RM. Analysis of primary health care utilisation in south-western Finland a tool for management. *Health Policy* 2003;**66**:229-38.
- 30 Finnish Cancer Registry. Numbers of prevalent cancers on 1 January 2011, by primary site and time after diagnosis. *http://www.cancer.fi/syoparekisteri/en/statistics/*. (accessed January 31, 2012).
- 31 Fink W, Lipatov V, Konitzer M. Diagnoses by general practitioners: Accuracy and reliability. *International Journal of Forecasting* 2009;**25**:784-93.
- 32 Grimsmo A, Hagman E, Faiko E, Matthiessen L, Njalsson T. Patients, diagnoses and processes in general practice in the Nordic countries. An attempt to make data from computerised medical records available for comparable statistics. *Scand J Prim Health Care* 2001;**19**:76-82.
- 33 Institut za Varovagne Zdravja Republike Slovenja. Zdravstveni statisticni letopis 2009. http://www.ivz.si/Mp.aspx?ni=45&pi=5&_5_id=1339&_5_PageIndex=0&_5_groupId=184&_5_ne wsCategory=&_5_action=ShowNewsFull&pl=45-5.0. (accessed July 19, 2011).

34	Nilsson GH, Mansson J, Ahlfeldt H, Gunnarsson R, Strender LE. Patients, general practitioners, diseases and health problems in urban general practice: a cross-sectional study on electronic patient records. <i>Primary Health Care Research & Development</i> 2008; 9 :119-25.
35	Royal College of Practitioners. Morbidity statistics from general practice: fourth national study 1991- 92. London: HMSO; 1995.
36	Paris V, Renaud T, Sermet C. Des comptes de la sante par pathologie: un prototype pour l'annee 1998. Paris: Dossiers Solidarite et Sante; 2003.
37	Federal Health Monitoring System. Total Cost of Illness in millions of Euro. Classification: years, gender, ICD10, provider. <i>www.gbe-bund.de</i> . (accessed May 11, 2011).
38	Public Health Forecasting of the National Institute for Public Health and the Environment. Kosten van Ziekten. <i>http://www.rivm.nl/vtv/object_document/o5417n26614.html</i> . (accessed July 29, 2011).
39	EUROSTAT. Harmonized indices of consumer prices (HICP). http://epp.eurostat.ec.europa.eu/portal/page/portal/hicp/data/database. (accessed May 11, 2011).
40	Kassenärztliche Bundesvereinigung (KBV). Sonstige Kostenträger. http://www.kbv.de/rechtsquellen/2350.html.
41	Bosmans JE, Boeke AJ, van Randwijck-Jacobze ME, Grol SM, Kramer MH, van der Horst HE, van Tulder MW. Addition of a general practitioner to the accident and emergency department: a cost-effective innovation in emergency care. <i>Emerg Med J</i> 2012; 29: 192-6.
42	Ministerio de Sanidad y Consumo. Conjunto minimo de datos - Ambulatorio. http://pestadistico.msc.es/PEMSC25/ArbolNodos.aspx. (accessed July 27, 2011).
43	EUROSTAT. Hospital discharges by diagnosis. http://epp.eurostat.ec.europa.eu/portal/page/portal/health/public_health/data_public_health/databas e. (accessed July 22, 2011).
44	van der Heyden J. Contacts ambulatoires avec le spécialiste. <i>https://www.wiv-isp.be/epidemio/epifr/crospfr/hisfr/his08fr/r3/4_contactsmedecinspecialiste_sp_report3_fr.pdf</i> . (accessed November 9, 2011).
45	Health Services Executive. Performance Report December 2009. http://www.hse.ie/eng/services/Publications/corporate/performancereports/Performance%20Report %20December%202009.pdf. (accessed December 15, 2011).
46	Ministry of Health of the Republic of Latvia. News No. 18. http://www.vnc.gov.lv/files/Health_Payment_Center_News_No_18.pdf. (accessed January 10, 2012).
47	World Health Organization Regional Office for Europe. European Health For All Database. <i>http://data.euro.who.int/hfadb/.</i> (accessed December 15, 2011).
48	Central Statistical Office of Poland. Statistical Yearbook of the Republic of Poland 2011. http://www.stat.gov.pl/gus/5840_737_ENG_HTML.htm. (accessed March 3, 2011).
49	Instituto Nacional de Estatistica. Consultas externas (N.º) nos hospitais por Localização geográfica e Especialidade da consulta. <i>www.ine.pt</i> . (accessed February 29, 2012).
50	Ministerio de Sanidad y Consumo. Estadistica de Establecimientos Sanitarios con Regimen de Internado. <i>http://pestadistico.msc.es/PEMSC25/ArbolNodos.aspx</i> . (accessed July 27, 2011).
51	Hospital Episode Statistics. Outpatient data - main specialty. http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=894. (accessed May 9, 2011).
	12

- 52 ISD Scotland. Specialty costs and activity consultant outpatients, by specialty, by board. http://www.isdscotland.org/Health-Topics/Finance/Costbook/Speciality-Costs/Outpatients.asp. (accessed January 22, 2012).
- 53 Welsh Assembly Government. Consultant lead out-patient clinics: summary data, all specialties. *http://statswales.gov.uk/index.htm*. (accessed May 10, 2011).
- 54 Northern Ireland Statistics & Research Agency. Northern Ireland Hospital Statistics: Outpatient Activity Statistics 2009/10. *http://www.dhsspsni.gov.uk/outpatient_activity_2009_10_revised_.pdf*. (accessed May 10, 2011).
- 55 The NHS Information Centre. Hospital Episode Statistics: Outpatient data main speciality. http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=890. (accessed February 1, 2012).
- Kalseth J, Halsteinli V, Halvorsen T, et al. Costs of cancer in the Nordic countries. http://www.sintef.no/Teknologi-ogsamfunn/Helse/Helsetjenesteforskning/Helseokonomi/Kostnadsanalyser-og-evaluering/Costs-ofcancer-in-the-Nordic-countries--A-comparative-study-of-health-care-costs-and-public-income-losscompensation-payments-related/ (accessed February 1, 2012).
- 57 Graham BJM. The cost of cancer care in Scotland 2002. Information Services Division Scotland; 2003.
- 58 Drieskens S. Contacts avec le service des urgences. *https://www.wiv-isp.be/epidemio/epifr/crospfr/hisfr/his08fr/r3/8_contactsservicedesurgances_ed_report3_fr.pdf*. (accessed November 9, 2011).
- 59 Hayes O, Novkov H. Emergency Health Services in Bulgaria. *Am J Emerg Med* 2002;**20**:122-5.
- 60 Federation Nationale des observatoires regionaux de sante. Activite des services d'urgence. *http://www.score-sante.org/score2008/sindicateurs.html*. (accessed August 3, 2011).
- 61 Statistisches Bundesamt. DRG-Statistik 2009 Vollstationäre Patientinnen und Patienten in Krankenhäusern. Hauptdiagnose nach Altersgruppen. (personal communication January 5, 2012).
- 62 Orszagos Egeszsegbiztositasi Penztar. Annual Report 2010. http://www.oep.hu/portal/page?_pageid=34,35856,34_37948182&_dad=portal&_schema=PORTA L. (accessed February 29, 2012).
- 63 Istituto Nazionale di Statistica. Hospital emergency service by region. http://en.istat.it/sanita/sociosan/index.html. (accessed January 12, 2012).
- 64 Inspectie voor de Gezondheidszorg. Ziekenhuizen goed op weg met implementatie normen voor afdelingen spoedeisende hulp. http://www.nvsha.nl/images/stories/actueel/nieuws/2012_Ziekenhuizen_goed_op_weg_met_impleme ntatie_normen_voor_afdelingen_spoedeisende_hulp1.pdf. (accessed January 16, 2012).
- 65 Central Statistical Office of Poland. Local Data Bank. First aid and emergency medical services: Emergency medical services and Out-patient activity of hospital emergency ward/admission room (NTS-2, 2004-2011). http://www.stat.gov.pl/bdlen/app/strona.html?p_name=indeks. (accessed August 5, 2011).
- 66 Instituto de Gestao Informatica e Financeira da Saude. Estatistica do movimento assistencial. Hospitais SNS. 2005. http://www.acss.minsaude.pt/Portals/0/DownloadsPublicacoes/SNS/Info_Activid/SNSa%C3%BAde.pdf. (accessed March 1, 2012).

67	National Institute of Statistics. Statistical Yearbook 2010. Chapter 7: Health. http://www.insse.ro/cms/files/Anuar%20statistic/07/07%20Sanatate_en.pdf. (accessed November 6, 2011).
68	Health Care Surveillance Authority . Emergency services in Slovakia. (personal communication January 5, 2012).
69	Northern Ireland Statistics & Research Agency. Northern Ireland Hospital Statistics: Emergency Care 2009/10. http://www.dhsspsni.gov.uk/index/stats_research/stats-activity_stats-2/emergency_care-3/hospital_statistics-3_emergency_care_annual.htm. (accessed May 10, 2011).
70	Hospital Episode Statistics. Accident and Emergency Attendances in England, 2009-10. http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=1502. (accessed May 10, 2011).
71	Statistics Denmark. Statistical Yearbook 2011. http://www.dst.dk/pukora/epub/upload/16218/sy2011.pdf. (accessed November 8, 2011).
72	Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. <i>Eur Heart J</i> 2006; 27 :1610-9.
73	Statistics Denmark. Admissions to hospitals by diagnosis and emergency/non-emergency. <i>http://www.statbank.dk/ud11</i> . (accessed August 1, 2011).
74	OECD. OECD Health Data 2010. 2010.
75	EUROSTAT. Hospital days of in-patients. http://epp.eurostat.ec.europa.eu/portal/page/portal/health/public_health/data_public_health/databas e. (accessed July 22, 2011).
76	EUROSTAT. Hospital discharges by diagnosis, day cases. http://epp.eurostat.ec.europa.eu/portal/page/portal/health/public_health/data_public_health/databas e. (accessed July 22, 2011).
77	EUROSTAT. Population on 1 January by five years age groups and sex. http://epp.eurostat.ec.europa.eu/portal/page/portal/population/data/database. (accessed March 3, 2011).
78	Arnaudova A. 10 health questions about the 10. http://www.euro.who.int/data/assets/pdf_file/0007/97414/E82865.pdf. (accessed October 6, 2011).
79	Tountas Y, Oikonomou N, Pallikarona G, et al. Sociodemographic and socioeconomic determinants of health services utilization in Greece: the Hellas Health I study. <i>Health Services Management Research</i> 2011; 24 :8-18.
80	Health Information Centre of Instutute of Hygiene. Health Statistics of Lithuania 2009. http://sic.hi.lt/data/la2009.pdf. (accessed January 18, 2012).
81	Health Information Centre of Instutute of Hygiene. Health Statistics of Lithuania 2009. http://sic.hi.lt/data/la2009.pdf. (accessed January 18, 2012).
82	Health Information Centre of Instutute of Hygiene. Health Statistics of Lithuania 2009. http://sic.hi.lt/data/la2009.pdf. (accessed January 18, 2012).
83	World Health Organisation Regional Office for Europe. European Health for All Database (HFA-DB), WHO/Europe. <i>http://data.euro.who.int/hfadb/</i> . (accessed August 5, 2011).

84 Institute of Health Information and Statistics of the Czech Republic. Czech Health Statistics Yearbook 2009. http://www.uzis.cz/en/publications/czech-health-statistics-yearbook-2009. (accessed November 14, 2011). 85 The NHS Information Centre. Accident and Emergency Attendances in England (Experimental Statistics) - 2009/10. http://www.ic.nhs.uk/pubs/aandeattendance0910. (accessed February 1, 2012). Hauptverband der osterreichischen Sozialversicherungstrager. Statistisches Handbuch der 86 osterreichischen Sozialversicherung 2011. http://www.hauptverband.at/mediaDB/819960 Statistisches%20Handbuch%20der%20oesterreichis chen%20Sozialversicherung.pdf. (accessed February 24, 12 A.D.). 87 Mossialos E, Merkur S, Ladurner J. Incentives and payment systems for physicians in selected countries with a special focus on Austria. Report for the Main Association of Austrian Social Security Institutions. http://www.hauptverband.at/mediaDB/MMDB136430_Incentives_Report_Chapter_2.pdf. (accessed February 24, 2012). Johansson G, Andeasson EB, Larsson PE, Vogelmeier CF. Cost effectiveness of 88 budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. *Pharmacoeconomics* 2006;24:695-708. 89 EUROSTAT. Health care expenditure by function. http://epp.eurostat.ec.europa.eu/portal/page/portal/health/public_health/data_public_health/databas e. (accessed July 22, 2011). 90 Institut National d'Assurance Maladie-Invalidité. Soins de Santé: Circulaire OA n° 2009/384 du 29 septembre 2009. http://inami.fgov.be/insurer/fr/rate/history/pdf/2009/doctors/raad20091001fr.pdf. (accessed February 27, 2011). 91 Institut National d'Assurance Maladie-Invalidité. Banque Nationale de Donnees: Diagnostic medical/Soins & Couts. https://tct.fgov.be/webetct/etct-web/html/fr/index.jsp. (accessed February 27, 2011). 92 Ministry of Health of the Republic of Cyprus. Price list/Charges. http://www.moh.gov.cy/Moh/moh.nsf/price_charges_en/price_charges_en?OpenDocument. (accessed January 13, 2012). 93 Institute of Health Information and Statistics of the Czech Republic. Economic information on health care 2009. http://www.uzis.cz/en/publications/economic-information-health-care-2009. (accessed November 14, 2011). 94 Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen trablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis a Northern European perspective. Clin Exp Allergy 2007;37:772-9. 95 Kronborg C, Vass M, Lauridsen J, Avlund K. Cost effectiveness of preventive home visits to the elderly. Eur J Health Econ 2006;7:238-246. 96 Hujanen T, Kapiainen S, Tuominen U, Pekurinen M. Terveydenhuollon yksikkokustannukset: Suomessa vuonna 2006. http://www.stakes.fi/verkkojulkaisut/tyopaperit/T3-2008-VERKKO.pdf. (accessed January 15, 2012). 97 Hammar T, Rissanen P, Perala ML. Home-care clients' needs for help, and use and costs of services. Eur J Ageing 2008;5:147-60. Giaquinto C, van Damme P, Huet F, Gothefors L, van der Wielen M. Costs of Community-Acquired 98 Pediatric Rotavirus Gastroenteritis in 7 European Countries: The REVEAL Study. J Infect Dis 2007;**195**:S36-S44.

- 99 McBride D, Mattenklotz AM, Willich SN, Bruggenjurgen B. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. *Value Health* 2009;**12**:293-301.
- 100 Syriopoulou V, Kafetzis D, Theodoridou M, Syrogiannopoulos GA, Mantagos S, Trimis G, Mavrikou M, Konstantopoulos A. Evaluation of potential medical and economic benefits of universal rotavirus vaccination in Greece. *Acta Paediatrica* 2011;**100**:732-9.
- 101 Athanaskakis K, Ollandezos M, Angeli A, Gregoriou A, Geitona M, Kyriopoulos J. Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost. *Diabet Med* 2010;**27**:679-84.
- 102 Gioldasis G, Talelli P, Chroni E, Daouli J, Papapetropoulos T, Ellul J. In-hospital direct cost of acute ischemic and hemorrhagic stroke in Greece. *Acta Neurol Scand* 2008;**118**:268-74.
- 103 Ersek K, Kovacs T, Wimo A, et al. Costs of dementia in Hungary. *J Nutr Health Aging* 2010;8:633-9.
- 104 Gannon B, O'Shea E, Hudson E. The economic costs of falls and fractures in people aged 65 and over in Ireland. Galway: Irish Centre for Social Gerontology; 2007.
- 105 Health Services Executive. Ready reckoner of acute hospital inpatient and daycase activity and costs. *http://www.hse.ie/eng/about/PersonalPQ/PQ/2008_PQ_Responses/May_2008/May_20_2008/Joe_M cHugh_PQ_19365-08_.pdf*. (accessed December 12, 2011).
- 106
 Department of Health. Acute Hospital Statistics: Health Statistics 2008.

 http://www.dohc.ie/statistics/pdf/stats08_acute.pdf?direct=1. (accessed January 13, 2012).
- 107 Ringborg A, Nieuwlaat R, Lindgren P, Jonsson B, Fidan D, Maggioni AP, Lopez-Sendon J, Stepinska J, Cokkinos DV, Crijns HJGM. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. *Europace* 2008; 10:403-411.
- 108 Societa Italiana di Medicina Specialistica. Tempi Medi di Attivita Modalita di Esecuzione Nomenclatore delle Prestazioni Specialistiche Ambulatoriali Territoriali. http://www.asppalermo.org/Archivio/circolari/dip_radiologia/SUMAIvolumiattivita.pdf. (accessed January 12, 2012).
- 109 Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the confronting COPD survey. *Respir Med* 2003;**97**:S43-S50.
- 110 Mercadante S, Intravaia G, Villari P, Ferrera P, David F, Mangione S. Clinical and financial analysis of an acute palliative care unit in an oncological department. *Palliat Med* 2008;**22**:760-7.
- Service Central de Legislation. Journal Officiel du Grand Duche de Luxembourg.
 http://www.legilux.public.lu/leg/a/archives/2009/0058/a058.pdf#page=2. (accessed January 15, 2012).
- 112 Polinder S, Toet H, Mulder S, van Beeck E. APOLLO: The economic consequences of injury. http://www.euroipn.org/apollo/reports/WP2.1Annex%2012%20Final%20report%20on%20The%20e conomic%20consequences%20of%20injury,%2006%20October%202008.pdf. (accessed July 12, 2012).
- 113 Tan SS, van Gils CWM, Franken MG, Hakkaart-van Roijen L, Uyl-de Groot CA. The Unit Costs of Inpatient Hospital Days, Outpatient Visits, and Daycare Treatments in the Fields of Oncology and Hematology. *Value Health* 2010;**13**:712-9.
- 114 Pietrasik A, Kosior DA, Niewada M, Opolski G, Latek M, Kaminski B. The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation. *Int J Cardiol* 2007;**118**:21-7.
- 115 Ministerio da Saude. Portaria n.º132-2009 de 30 de Janeiro. *Diario da Republica* 2009; 1.ª serie.

- 116 Administração Central do Sistema de Saúde. Base de Dados dos Elementos Analíticos (BDEA): Custos unitarios. *http://www.acss.min-saude.pt/bdea/*. (accessed March 1, 2012).
- 117 World Health Organisation. CHOosing Interventions that are Cost Effective (WHO-CHOICE): Country-specific unit costs. *http://www.who.int/choice/country/country_specific/en/index.html*. (accessed August 5, 2011).
- 118 Martinez-Moragon E, Serra-Battles J, De Diego A, et al. Economic cost of treating the patient with asthma in Spain: The AsmaCost Study. *Arch Bronconeumol* 2009;**45**:481-6.
- Sveriges Kommuner och Landsting. Statistik om hälso- och sjuk vård samt regional utveckling 2009.
 Verksamhet och ekonomi i landsting och regioner.
 http://brs.skl.se/brsbibl/kata_documents/doc39788_1.pdf. (accessed March 5, 2012).
- 120 Mesterton J, Jansson L, Almer SHC, Befrits R, Friis-Liby I, Lindgren S. Resource use and societal costs for Crohn's disease in Sweden. *Inflamm Bowel Dis* 2009;**15**:1882-90.
- 121 Curtis L. Unit costs of health and social care 2009. Canterbury, Kent: Personal Social Services Research Unit; 2009.
- 122 National Health Service. NHS Reference Costs 2008-09. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH _111591. (accessed May 9, 2011).
- 123 Golna C, Pashardes P, Allin S, Theodorou M, Merkur S, Mossialos E. Health Care Systems in Transition: Cyprus. Copenhaguen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2004.
- 124 Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. *Int J Cancer* 2013;**132**:1133-45.
- 125 Borsch-Supan A, Kafetzis D. The Survey of Health, Ageing and Retirement in Europe -Methodology. http://www.shareproject.org/t3/share/uploads/tx_sharepublications/SHARE_BOOK_METHODOLOGY_Wave1.pdf. (accessed July 16, 2012).
- 126 EUROSTAT. Causes of death Absolute numbers. *http://epp.eurostat.ec.europa.eu/portal/page/portal/health/public_health/data_public_health/databas e.* (accessed July 22, 2011).
- 127 EUROSTAT. Employment by sex, age groups and nationality. *http://epp.eurostat.ec.europa.eu/portal/page/portal/employment_unemployment_lfs/data/database*. (accessed March 3, 2011).
- 128 EUROSTAT. Average annual gross earnings by economic activity Nace Rev. 2. http://epp.eurostat.ec.europa.eu/portal/page/portal/labour_market/earnings/database. (accessed March 3, 2011).
- 129 EUROSTAT. Average annual gross earnings by occupation. http://epp.eurostat.ec.europa.eu/portal/page/portal/labour_market/earnings/database. (accessed March 3, 2011).
- 130 Statistics Austria. Structure of Earnings Survey. http://www.statistik.at/web_en/statistics/social_statistics/personal_income/structure_of_earnings/ind ex.html. (accessed March 10, 2011)
- 131 Republic of Cyprus Statistical Service. Average monthly earnings of employees by quarter. http://www.mof.gov.cy/mof/cystat/statistics.nsf/labour_31main_en/labour_31main_en?OpenForm&s ub=1&sel=2. (accessed March 10, 2011).

- 132 Istituto Nazionale di Statistica. Gross earnings in enterprises with more than 500 employees monthly data. *http://dati.istat.it/?lang=en.* (accessed November 11, 2011).
- 133 National Statistical Service of Greece. Statistical Yearbook of Greece 2008. http://dlib.statistics.gr/Book/GRESYE_01_0002_00060.pdf. (accessed January 27, 2012).
- 134 EUROSTAT. Monthly minimum wages bi-annual data. http://epp.eurostat.ec.europa.eu/portal/page/portal/labour_market/earnings/database. (accessed March 3, 2011).
- 135 Statistics Denmark. Earnings for employees in the private sector by occupation, group of employees, age and sex. *http://www.statbank.dk/statbank5a/default.asp?w=1280*. (accessed March 10, 2011).
- 136 International Labor Organization. Occupational wages and hours of work. *http://laborsta.ilo.org/STP/guest.* (accessed March 10, 2011).
- 137 Statistics Austria. Statistisches Jahrbuch Österreichs. http://www.statistik.at/web_en/publications_services/statistisches_jahrbuch/index.html. (accessed June 13, 2011).
- 138 Institut National d'Assurance Maladie-Invalidité. 5e Partie Donnees Statistiques: Soins de Sante. *http://www.riziv.be/presentation/fr/publications/annual-report/2010/pdf/ar2010p5.pdf.* (accessed November 11, 2011).
- Tomev L. Absence from work Bulgaria.
 http://www.eurofound.europa.eu/ewco/studies/tn0911039s/bg0911039q.htm. (accessed December 6, 2011).
- 140 Institute of Health Information and Statistics of the Czech Republic. Ukoncene pripady paracovni neschopnosti pro nemoc a uraz 2010. *http://www.uzis.cz/katalog/zdravotnicka-statistika/ukoncene-pripady-pracovni-neschopnosti-pro-nemoc-uraz.* (accessed November 14, 2011).
- 141 Statistics Denmark. Absence by sector, sex, cause of absence, age and indicator of absence. *http://www.statbank.dk/FRA05*. (accessed August 1, 2011).
- 142 Kela The Social Insurance Fund. Sickness allowance: Number of recipients and allowances paid out. *http://www.kela.fi/in/internet/english.nsf/alias/kelasto_content#Sickness*. (accessed November 1, 2011).
- 143 Federal Statistical Office of Germany. Quality of employment Earning money and what else counts. Wiesbaden: Statistiches Bundesamt; 2011.
- 144 Hungarian Central Statistical Office. Health insurance, sick pay. http://statinfo.ksh.hu/Statinfo/themeSelector.jsp?page=2&szst=FSP. (accessed January 27, 2012).
- 145
 Irish Business and Employers Confederation. Absence and Sick Pay.

 http://www.ibec.ie/IBEC/ES.nsf/vPages/Employment_law~During_employment~absence-and-sick-leave?OpenDocument. (accessed December 12, 2011).
- Giaccone M. Absence from work Italy.
 http://www.eurofound.europa.eu/ewco/studies/tn0911039s/it0911039q.htm. (accessed December 6, 2011).
- 147 Curkina I, Berdnikovs A. Absence from work Latvia.
 http://www.eurofound.europa.eu/ewco/studies/tn0911039s/lv0911039q.htm. (accessed January 9, 2012).

148	Blaziene I. Absence from work - Lithuania. http://www.eurofound.europa.eu/ewco/studies/tn0911039s/lt0911039q.htm. (accessed January 6, 2012).
149	Inspection General de la Securite Sociale. Situation de l'absenteisme pour cause de maladie en 2010. <i>http://www.observatoire-absenteisme.public.lu/chiffres_cles/Absenteisme_maladie_2009.pdf</i> . (accessed January 5, 2012).
150	Borg A, Caruana C. Absence from work - Malta. http://www.eurofound.europa.eu/ewco/studies/tn0911039s/mt0911039q.htm. (accessed January 5, 2012).
151	Statistics Netherlands. Labour and Social Security. http://www.cbs.nl/en-GB/menu/themas/arbeid-sociale-zekerheid/nieuws/default.htm. (accessed August 1, 2011).
152	Zaklad Ubezpieczen Spolecznych - Department Statystyki. Absencja Chorobowa W 2007 Roku. http://www.zus.pl/files/Absencja2007_wynikpracy.pdf. (accessed January 5, 2012).
153	Ministerio do Trabalho e da Solidariedade Social. Balanco social 2007. http://www.gep.msss.gov.pt/estatistica/gerais/bs2007pub.pdf. (accessed November 13, 2011).
154	Ciutacu C. Absence from work - Romania. http://www.eurofound.europa.eu/ewco/studies/tn0911039s/ro0911039q.htm. (accessed January 5, 2012).
155	Chartered Institute of Personnel and Development. Absence Management. <i>http://www.cipd.co.uk/binaries/4926%20Absence%20SR%20%28WEB%29.pdf</i> . (accessed May 11, 2011).
156	Eesti Haigekassa. Ajutsie Toovoimetuse Huvitise Kulud Kulusid Mojutavad Oluliseimad Naitajad. http://www.haigekassa.ee/files/est_haigekassa_statistika/TVH_2003_2006_korrigeeritud_vastavalt_j uhatuse_ettepanekutele.pdf. (accessed November 11, 2011).
157	Vahtera J, Westerlund H, Ferrie JE, Head J, Melchior M, Singh-Manoux A, Zins M, Goldberg M, Alexanderson K, Kivimaki M. All-cause and diagnosis-specific sickness absence as a predictor of sustained suboptimal health: a 14-year follow-up in the GAZEL cohort. <i>J Epidemiol Community Health</i> 2010; 64 :311-7.
158	Federal Health Monitoring System. Inability to work of compulsory members of the Local Statutory Health Insurance (AOK) without pensionsers (cases and days of inability to work, days per case). <i>www.gbe-bund.de</i> . (accessed May 6, 2011).
159	Barbini N, Beretta GG, Minnucci MP, Andreani M. Le principali patologie causa di assenza dal lavoro. Analisi della banca dati INPS. <i>G Ital Med Lav Erg</i> 2006; 28 :14-9.
160	Roelen CAM, Koopmans PC, Anema JR, van der Beek AJ. Recurrence of Medically Certified Sickness Absence According to Diagnosis: A Sickness Absence Register Study. <i>J Occup Rehabil</i> 2010; 20 :113-21.
161	Institut za Varovagne Zdravja Republike Slovenja. Odsotnost z dela zaradi zdravstveno opravicenih razlogov. http://www.ivz.si/Mp.aspx?ni=187π=5&_5_id=297&_5_PageIndex=0&_5_groupId=318&_5_ne wsCategory=&_5_action=ShowNewsFull&pl=187-5.0. (accessed July 20, 2011).
162	Oliva J. Perdidas laborales ocasionadas por las enfermedades y problemas de salud en Espana en el ano 2005. <i>http://www.minhac.es/ief/principal.htm</i> . (accessed August 3, 2011).
163	Lidwall U. Long-term sickness absence: Aspects of society, work and family. Stockholm: Karolinska Institutet; 2010.
	19

16	 Kela - The Social Insurance Fund. Recipients of disability benefit by diagnosis. http://www.kela.fi/in/internet/english.nsf/alias/kelasto_content#Disability. (accessed November 1, 2011).
16	5 Department for Works and Pensions. Days of certified incapacity in the period 01.04.01 to 31.03.02, analysed by sex and diagnosis. London: Department for Works and Pensions, 2006.
16	6 Cuerq A, Paita M, Ricordeau P. Les causes medicales de l'invalidite en 2006. Paris: Caisse Nationale de l'Assurance Maladie; 2008. Report No.: Poits de Repere 16.
16	 National Institute of Statistics. Social Protection and Assistance. http://www.insse.ro/cms/files/Anuar%20statistic/06/06%20Securitate%20si%20asistenta%20sociala _en.pdf. (accessed December 6, 2011).
16	 Czech Statistical Office. Statistical Yearbook of the Czech Republic 2010. <i>http://www.czso.cz/csu/2010edicniplan.nsf/engkapitola/0001-102500</i>. (accessed November 15, 2011).
16	9 OECD. Sickness, disability and work: Breaking the barriers. http://www.oecd.org/dataoecd/30/58/46460721.pdf. (accessed November 9, 2011).
17	Statistics Estonia. Statistical Yearbook of Estonia 2009. <i>http://www.stat.ee/31366</i> . (accessed November 14, 2011).
17	National Statistical Service of Greece. Pensioners receiving principal pension from the social insurance organizations, by categoy of pension. <i>http://www.statistics.gr/portal/page/portal/ESYE/PAGE-themes?p_param=A2104</i> . (accessed January 27, 2012).
17	 Hungarian Central Statistical Office. Yearbook of Welfare Statistics, 2010. <i>http://portal.ksh.hu/pls/ksh/ksh_web.shop.dok?p_id=9502&p_mezo=MINTA</i>. (accessed January 27, 2012).
17	3 Department of Social Protection. Statistical Information on Social Welfare Services 2009. http://www.welfare.ie/EN/Policy/ResearchSurveysAndStatistics/Documents/2009stats.pdf. (accessed January 27, 2012).
17	4 Istituto Nazionale di Statistica. Pensions. <i>http://dati.istat.it/?lang=en</i> . (accessed December 6, 2011).
17.	5 Latvijas Statistika. Pension recipients by age and by type of pension. http://data.csb.gov.lv/DATABASEEN/Iedzsoc/Annual%20statistical%20data/12.%20Social%20secur ity/12.%20Social%20security.asp. (accessed January 9, 2012).
17	6 Lietuvos Statistikos Departamentas. Beneficiaries, by sex, category of benefit and year. http://db1.stat.gov.lt/statbank/SelectTable/Omrade0.asp?PLanguage=1. (accessed January 6, 2012).
17	7 Central Statistical Office. Incapacity to work. http://www.stat.gov.pl/bdlen/app/strona.html?p_name=indeks. (accessed January 5, 2012).
17	8 Statisticky Urad Slovenskej Republiky. Number of invalidity pensions paid. http://www.statistics.sk/pls/elisw/metainfo.explorer. (accessed December 6, 2011).
17	9 Instituto Nacional de Estadistica. Indicadores Sociales 2009. <i>http://www.ine.es/ine/ine.htm</i> . (accessed August 3, 2011).
18	Department for Works and Pensions. Incapacity Benefit and Severe Disablement Allowance Quarterly Summary of Statistics. <i>http://research.dwp.gov.uk/asd/index.php?page=ib_sda</i> . (accessed May 11, 2011).

B. Results

Table B.1 Average unit costs (€), by country, 2009

Country	Mortal	ity losses	Morbidity losses	Inform		Health care	unit costs		
	Yearly	earnings	Daily earnings	Hourly e	GP	Outpatient	A&E	Inpatient	
							visit	visit	day
	Males	Females		Carers in	Carers not in				
				employment	employment				
Austria	3/ 982	21 520	125	16	10	45	58	121	116
Relgium	41 748	35 659	125	21	0	26	53	70	499
Bulgaria	4 181	3 3 5 7	170	21	1	6	17	27	74
Cyprus	25 333	20,307	100	13	6	15	21	44	284
Czech Ren	12 108	9,096	47	6	2	9	14	71	187
Denmark	58 747	46 344	230	29	11	18	81	144	663
Estonia	11 602	8 254	43	5	2	16	44	116	166
Finland	39,000	31,908	154	19	11	62	240	252	656
France	34,146	25,118	130	16	9	33	125	85	843
Germany	46.697	35.654	181	23	10	22	81	105	545
Greece	31,935	21.611	121	15	6	23	53	57	378
Hungary	11.270	7,964	42	5	2	4	5	62	91
Ireland	45,405	33.073	173	22	10	49	168	203	826
Italy	29,325	23,735	118	15	7	22	71	72	643
Latvia	8,623	7,218	34	4	2	8	32	36	98
Lithuania	7,734	6,711	31	4	2	9	22	38	70
Luxembourg	57,576	47,363	231	29	11	36	56	72	830
Malta	17,647	14,712	72	9	4	32	50	98	325
Netherlands	45,163	33,738	174	22	9	39	109	148	531
Poland	10,334	8,404	41	5	2	13	53	30	185
Portugal	19,276	16,815	79	10	3	31	85	86	194
Romania	5,436	5,025	23	3	1	8	11	61	58
Slovakia	11,291	8,396	44	5	2	17	24	33	150
Slovenia	18,048	16,043	74	9	4	23	34	96	330
Spain	25,437	21,188	103	13	5	35	74	139	363
Sweden	36,246	29,721	144	18	12	115	381	237	468
UK	35,706	20,519	124	16	7	37	131	116	516

Country		Mor	tality losses		Morbidity losses	Informa		Healthcar	e contacts		
	Dea	ths	Working ye	ears lost	Working days lost	Care h	Care hours		Outpatient visits	A&E visits	Inpatient days
	М	F	М	F		Carers in employment	Carers not in employment		-		
Austria	2.57	2.14	6	3	131	1,542	4,339	89	111	22	201
Belgium	2.87	2.04	4	2	331	776	3,868	125	122	12	103
Bulgaria	2.71	1.79	7	4	206	1,092	2,218	225	95	8	100
Cyprus	1.63	1.22	5	3	65	726	1,714	27	60	37	53
Czech Rep.	3.02	2.29	7	3	337	1,172	2,393	305	516	19	145
Denmark	2.81	2.59	5	4	300	738	2,560	43	124	14	82
Estonia	3.07	2.25	7	5	585	1,454	2,705	359	163	44	120
Finland	2.22	1.91	4	3	94	544	1,882	63	114	15	132
France	2.90	1.91	4	3	275	788	3,064	54	22	4	68
Germany	2.90	2.38	6	4	149	1,675	3,945	392	255	3	218
Greece	3.01	1.85	6	2	63	661	3,719	221	209	39	137
Hungary	3.82	2.73	8	4	113	1,243	3,241	687	387	8	133
Ireland	2.08	1.69	6	3	82	702	2,218	148	40	14	113
Italy	3.21	2.31	5	2	20	1,917	8,920	366	107	27	107
Latvia	3.04	2.28	8	6	257	1,367	2,644	275	103	29	153
Lithuania	2.94	1.98	7	4	378	1,216	2,495	267	109	30	129
Luxembourg	2.26	1.94	4	2	158	742	2,820	230	260	16	129
Malta	2.24	1.79	4	1	39	761	3,444	57	49	11	48
Netherlands	2.76	2.26	6	4	247	1,082	3,962	264	139	5	154
Poland	2.85	2.07	7	3	246	1,427	3,512	259	182	13	88
Portugal	2.80	1.82	12	5	116	1,362	3,458	131	71	30	88
Romania	2.67	1.74	11	5	165	1,151	2,063	111	252	2	107
Slovakia	2.55	1.84	6	3	375	1,016	2,176	315	534	19	113
Slovenia	3.21	2.44	8	4	477	1,135	2,584	73	108	27	123
Spain	2.79	1.66	5	2	102	1,208	4.006	478	100	33	77
Sweden	2.46	2.23	5	4	358	824	2,363	44	69	18	94
UK	2.72	2.37	6	4	89	1,024	3,195	68	133	6	92
TOTAL EU	2.87	2.13	6	3	166	1,262	4,015	248	156	14	119

Table B.2. Cancer-related resource units per 1,000 population in the EU, by country, 2009

Country	Cancer-related healthcare costs per capita							
	Primary	Outpatient	A&E	Inpatient care	Medications	Total		
	care	care		-		healthcare		
Austria	4	6	3	90	41	144		
Belgium	3	6	1	51	32	94		
Bulgaria	1	2	0.2	7	6	16		
Cyprus	0.4	1	1	15	27	45		
Czech Rep.	3	7	1	27	19	57		
Denmark	1	10	2	54	37	104		
Estonia	6	7	5	20	8	45		
Finland	4	27	4	86	29	151		
France	2	3	0.3	58	47	110		
Germany	9	21	0.4	119	33	182		
Greece	5	11	2	52	40	111		
Hungary	3	2	1	12	22	39		
Ireland	7	7	3	94	28	139		
Italy	8	8	2	69	28	114		
Latvia	2	3	1	15	5	26		
Lithuania	2	2	1	9	3	18		
Luxembourg	8	15	1	107	52	184		
Malta	2	2	1	16	18	39		
Netherlands	10	15	1	82	22	130		
Poland	3	10	0.4	16	7	37		
Portugal	4	6	3	17	23	53		
Romania	1	3	0.1	6	10	20		
Slovakia	5	13	1	17	21	57		
Slovenia	2	4	3	41	23	72		
Spain	17	7	5	28	33	90		
Sweden	5	26	4	44	25	105		
UK	2	17	1	47	17	85		
TOTAL EU	6	11	1	.57	_ 27	102		

Table B.3. Total healthcare costs of cancer (€) by category of resource use and per capita, 2009

Country	Healthcare costs						Productivity lo	sses	Informal	TOTAL
	Primary	Outpatient	A&E	Inpatient care	Medications	Total	Mortality	Morbidity	care	costs
	care	care				healthcare				
Austria	4	6	2	82	12	107	175	16	89	387
Belgium	4	8	1	63	12	88	286	68	114	555
Bulgaria	1	1	0.1	3	2	6	31	1	4	42
Cyprus	<0.1	0.1	0.1	1	1	2	13	1	2	18
Czech Rep.	3	8	1	33	7	52	97	6	15	171
Denmark	1	8	1	35	7	52	236	46	57	391
Estonia	1	1	1	3	0.4	5	12	3	2	22
Finland	0.4	11	2	42	6	61	79	7	23	170
France	8	13	1	337	108	468	1,294	160	399	2,321
Germany	75	180	4	958	124	1,341	2,728	139	880	5,087
Greece	8	18	4	60	21	110	282	9	79	479
Hungary	4	3	1	21	8	37	130	10	22	200
Ireland	3	3	1	45	5	57	117	6	29	209
Italy	43	40	10	402	60	554	824	11	1,015	2,404
Latvia	0.4	1	0.2	3	0.4	5	16	2	3	26
Lithuania	1	1	0.3	2	0.3	5	19	2	4	29
Luxembourg	1	1	0.1	8	1	10	16	2	4	33
Malta	0.1	0.1	<0.1	0.4	0.2	1	2	0.1	1	5
Netherlands	17	25	1	157	9	211	619	84	182	1,096
Poland	21	61	2	97	10	191	358	59	108	716
Portugal	3	4	2	15	9	33	237	8	35	313
Romania	2	7	0.3	15	7	32	166	9	16	222
Slovakia	3	9	0.4	11	4	27	33	3	7	70
Slovenia	0.4	1	1	8	2	12	33	7	6	58
Spain	25	11	7	125	54	222	738	48	249	1,258
Sweden	4	20	3	41	8	76	143	48	48	315
UK	10	105	4	304	38	461	1,238	56	424	2,179
TOTAL EU	242	544	51	2,874	515	4,227	9,922	813	3,817	18,779

Table B.4 Costs of lung cancer (€ million) in the EU, by country, 2009

Country	Healthcare	costs				Productivity lo	sses	Informal	TOTAL	
	Primary	Outpatient	A&E	Inpatient care	Medications	Total	Mortality	Morbidity	care	costs
	care	care				healthcare				
Austria	4	7	3	103	14	132	60	13	63	268
Belgium	4	8	1	102	14	129	67	53	66	315
Bulgaria	1	1	0.2	7	2	11	11	3	4	30
Cyprus	0.1	0.2	0.2	2	1	3	3	1	2	9
Czech Rep.	5	12	2	49	8	76	47	1	16	141
Denmark	1	8	1	46	8	64	106	59	36	266
Estonia	1	1	1	6	0.4	8	5	3	2	19
Finland	2	15	2	55	6	80	35	7	19	141
France	11	17	2	508	125	664	308	189	301	1,461
Germany	71	170	4	1,372	114	1,730	1,015	219	801	3,765
Greece	6	13	3	51	19	92	48	8	33	181
Hungary	5	4	1	20	9	39	39	6	18	101
Ireland	4	4	2	55	5	69	63	6	19	158
Italy	52	48	12	600	69	782	345	16	641	1,783
Latvia	1	1	0.3	4	0.5	6	6	2	3	17
Lithuania	1	1	1	4	0.4	7	6	4	4	21
Luxembourg	1	1	0.1	8	1	11	5	2	3	21
Malta	0.2	0.3	0.1	1	0.3	2	1	0.3	1	4
Netherlands	19	28	2	212	14	276	236	86	121	719
Poland	17	57	2	81	11	169	101	38	66	374
Portugal	5	8	3	31	10	58	123	17	40	236
Romania	2	8	0.3	18	8	37	48	11	14	110
Slovakia	4	11	1	14	5	34	17	1	7	59
Slovenia	0.4	1	1	11	2	15	15	7	6	43
Spain	74	32	20	226	63	414	259	56	219	948
Sweden	3	15	2	33	10	63	230	39	78	410
UK	4	121	4	422	44	595	568	72	256	1,492
TOTAL EU	298	593	70	4,040	565	5,566	3,769	921	2,837	13,092

Table B.5 Costs of colorectal cancer (€ million) in the EU, by country, 2009

Country	Healthcare	costs			Productivity lo	sses	Informal	TOTAL		
	Primary	Outpatient	A&E	Inpatient care	Medications	Total	Mortality	Morbidity	care	costs
	care	care				healthcare				
Austria	4	6	2	74	72	158	43	15	66	282
Belgium	4	9	1	46	73	133	100	59	74	365
Bulgaria	1	1	0.2	6	9	18	7	3	5	33
Cyprus	<0.1	0.1	0.1	1	5	6	5	1	2	13
Czech Rep.	3	7	1	23	41	74	20	21	21	137
Denmark	1	7	1	20	43	71	78	25	35	209
Estonia	1	1	1	4	2	10	5	6	3	23
Finland	5	19	3	45	33	104	50	9	25	188
France	15	24	3	289	634	965	437	760	336	2,497
Germany	102	243	2	1,217	777	2,342	913	618	1,073	4,946
Greece	5	11	2	43	130	191	43	6	34	274
Hungary	2	2	0.4	8	46	58	23	3	20	104
Ireland	3	3	1	32	27	66	43	6	22	137
Italy	44	41	10	193	349	636	292	9	609	1,546
Latvia	1	1	0.4	5	2	9	8	3	4	24
Lithuania	1	1	0.4	3	2	7	9	5	5	25
Luxembourg	1	1	0.1	6	5	13	3	2	4	22
Malta	0.1	0.1	<0.1	0.3	2	2	1	0.1	1	5
Netherlands	18	26	1	216	47	309	206	51	140	705
Poland	11	33	1	58	56	160	64	40	70	333
Portugal	4	6	3	10	52	74	74	5	32	186
Romania	2	6	0.2	11	43	62	38	7	20	126
Slovakia	2	6	0.3	8	23	40	8	12	9	69
Slovenia	0.3	1	0.4	5	10	16	9	5	6	36
Spain	80	35	21	64	317	518	199	32	219	969
Sweden	5	24	4	23	49	104	90	27	59	279
UK	11	113	4	233	221	581	487	59	309	1,437
TOTAL EU	325	626	65	2,641	3,068	6,725	3,254	1,788	3,204	14,971

Table B.6 Costs of breast cancer (€ million) in the EU, by country, 2009

Country	Healthcare	costs					Productivity lo	sses	Informal	TOTAL
	Primary	Outpatient	A&E	Inpatient care	Medications	Total	Mortality	Morbidity	care	costs
	care	care				healthcare				
Austria	2	3	1	40	75	120	13	6	41	179
Belgium	2	5	1	31	75	115	16	26	43	200
Bulgaria	0.2	0.2	<0.1	1	9	11	1	0.4	3	15
Cyprus	<0.1	<0.1	0.1	0.4	2	3	2	< 0.1	1	6
Czech Rep.	2	4	1	16	42	65	8	7	11	91
Denmark	0.3	4	1	14	45	64	24	18	26	131
Estonia	0.3	0.4	0.3	2	2	5	1	1	2	9
Finland	3	10	1	38	34	88	8	3	16	114
France	9	14	2	273	658	956	46	61	207	1,271
Germany	54	130	1	812	745	1,743	217	152	577	2,688
Greece	3	6	1	24	125	159	10	4	24	197
Hungary	1	0.5	0.1	3	48	52	3	1	10	65
Ireland	1	1	1	20	28	51	15	2	14	81
Italy	25	24	6	175	362	592	45	5	344	985
Latvia	0.2	0.4	0.1	2	2	5	2	1	2	9
Lithuania	1	1	0.3	3	2	6	2	3	3	14
Luxembourg	0.2	0.4	<0.1	3	6	9	0.3	1	2	13
Malta	<0.1	<0.1	<0.1	0.1	1	2	0.1	< 0.1	1	2
Netherlands	9	13	1	65	57	145	48	15	84	292
Poland	4	10	0.4	21	58	94	22	7	40	162
Portugal	2	3	1	6	54	65	29	3	24	121
Romania	1	2	0.1	3	45	50	7	2	10	69
Slovakia	1	2	0.1	3	24	31	2	4	5	41
Slovenia	0.2	1	0.4	5	10	16	4	3	4	26
Spain	49	22	13	41	330	455	27	12	132	626
Sweden	5	25	4	35	51	120	27	41	48	237
UK	5	51	2	126	229	413	153	13	203	783
TOTAL EU	181	332	38	1,762	3,119	5,433	732	391	1,875	8,431

Table B.7 Costs of prostate cancer (€ million) in the EU, by country, 2009

Highest expenditure	All cancers	All cancers	Lung cancer	Colorectal cancer	Breast cancer	Prostate cancer	
per capita	(unadjusted)	(PPP-adjusted)	(PPP-adjusted)	(PPP-adjusted)	(PPP-adjusted)	(PPP-adjusted)	Rank
	Luxembourg	Germany	Luxembourg	Germany	Germany	Germany	1
T	Germany	Luxembourg	Germany	Luxembourg	Greece	Greece	2
	Finland	Greece	Netherlands	Netherlands	Luxembourg	Luxembourg	3
	Austria	Finland	Greece	Czech Rep.	Netherlands	Finland	4
	Ireland	Netherlands	Poland	Austria	Finland	France	5
	Netherlands	Austria	Austria	Finland	Austria	Austria	6
iita	Italy	Czech Rep.	Finland	Slovakia	Slovakia	Sweden	7
cap	Greece	Slovakia	Slovakia	Estonia	France	Czech Rep.	8
er	France	France	Czech Rep.	Italy	Czech Rep.	Spain	9
t p	Sweden	Spain	Ireland	UK	Estonia	Hungary	10
sos	Denmark	Italy	UK	Ireland	Spain	Slovakia	11
e	Belgium	Sweden	Italy	Spain	Hungary	Slovenia	12
cai	Spain	UK	Hungary	Greece	UK	Netherlands	13
tt	UK	Slovenia	Slovenia	Poland	Sweden	Italy	14
Jea	Slovenia	Ireland	Sweden	Slovenia	Slovenia	Belgium	15
st]	Czech Rep.	Estonia	Estonia	France	Ireland	Denmark	16
the	Slovakia	Hungary	France	Belgium	Belgium	Ireland	17
bid	Portugal	Poland	Denmark	Hungary	Malta	UK	18
2	Estonia	Belgium	Belgium	Denmark	Italy	Portugal	19
est	Cyprus	Denmark	Spain	Malta	Poland	Estonia	20
MC	Hungary	Portugal	Latvia	Portugal	Denmark	Romania	21
ol c	Malta	Malta	Romania	Sweden	Latvia	Malta	22
UO IO	Poland	Bulgaria	Portugal	Latvia	Portugal	Poland	23
丘	Latvia	Latvia	Malta	Bulgaria	Bulgaria	Bulgaria	24
	Romania	Romania	Lithuania	Romania	Romania	Latvia	25
	Lithuania	Cyprus	Cyprus	Lithuania	Cyprus	Cyprus	26
•	Bulgaria	Lithuania	Bulgaria	Cyprus	Lithuania	Lithuania	27

 Table B.8 Countries ranked in terms of cancer-related healthcare expenditure per capita

Figure B.1 Tornado plot of the results of the sensitivity analysis on the total costs of cancer in the EU, € billions, 2009



The horizontal axis represents the total costs of cancer in the EU. The categories/parameters being changed are displayed along the vertical axis. The horizontal bars represent the range in total costs associated with the specified change for each category/parameter, e.g. $\pm 20\%$ change in earnings across all EU countries or $\pm 50\%$ change in healthcare resource use in countries without direct cancer data. Blue bar represents reduction and the red bar represents increase in total costs of cancer associated with the value of the category being changed. The labels represent the upper and lower bounds of total costs of cancer for a given category/parameter. The base-case total costs of cancer (using the reported data, €126 billion) are indicated by a vertical line cutting through the horizontal bars.





Figure B.3 Correlation between cancer healthcare expenditure (€) and national income (€, as measured using Gross Domestic Product – GDP)



Figure B.4 Correlation between cancer healthcare expenditure (€) and cancer incidence (crude)



Figure legend: AT Austria; BE Belgium; BG Bulgaria; CY Cyprus; CZ Czech Republic; DE Germany; DK Denmark; EE Estonia; EL Greece; ES Spain; FI Finland; FR France; HU Hungary; IE Ireland; IT Italy; LU Luxembourg; LT Lithuania; LV Latvia; MT Malta; NL the Netherlands; PL Poland; PT Portugal; RO Romania; SE Sweden; SI Slovenia; SK Slovakia; UK United Kingdom.



Figure B.5 Total costs by cancer type, € million, 2009







Figure B.7 Healthcare costs per capita (€) by cancer type and healthcare service category, 2009, adjusted for price differentials (PPP)